Recently, several early phase studies of PD-(L)1 -based therapies have been explored in cHL patients who had previously received PD-(L) blockade showed promising outcomes, such as the study of favezelimab (anti-LAG-3) plus permbrolizumab15, sabestomig (binding to PD-1 and T cell immunoglobulin and mucin-domain containing protein-3 [TIM-3])16, CC-486 (hypomethylating agent) plus nivolumab17, and decitabine plus camrelizumab18. This evidence concerns the gene LAG3 and classic Hodgkin lymphoma.